Skip links

Altimetrik featured in Gartner’s Market Guide for Data Science and Machine Learning Service Providers

Jump To Section

Gartner published their Market Guide for Data Science and Machine Learning (DS&ML) Service Providers on 31st Oct, 2017 and featured Altimetrik on a list of 32 most visible DS&ML providers in the world.

Altimetrik featured in Gartner’s Market Guide for Data Science and Machine Learning Service Providers

Gartner published their Market Guide for Data Science and Machine Learning (DS&ML) Service Providers on 31st Oct, 2017 and featured Altimetrik on a list of 32 most visible DS&ML providers in the world.

The guide focuses on support that data science and machine learning projects need and how enterprises can engage with service providers to fill the analytics deficit and augment their existing data scientists with specific skills. Vendors featured in the report were evaluated based on their Market Presence, Projects, Capabilities, Innovation, IP’s and Engagement models.

Altimetrik’s Analytical Methods and Strategic Consulting

Altimetrik has adopted major analytical methods like Machine learning, deep learning, NLP optimization and chatbots across key industries with strategy and consulting capabilities in use case identification, maturity assessment and roadmap and in building business domain expertise.

Our primary differentiators, which also map with some of the “Market Recommendations” section of this report, are:

  • A differentiated approach – Gartner cites a common issue with “BI teams significantly overestimate or underestimate their ability to support data science projects.” Our approach is entirely different in this respect in the way we initiate and whiteboard a project before getting to the resource identification or technical need. Our strategy and consulting methodology helps cut down flab in this kind of a project and keeps efforts streamlined.
  • Focus on predictive and prescriptive analytics – It is reassuring to see Gartner emphasizing on the need to augment descriptive and diagnostic analytics into predictive and prescriptive methods for better business outcomes. This is at the core of our capability and focus for all research and development.
  • Flexibility in every sense – As a young and nimble company, Altimetrik is suitable for organizations of different sizes, in terms of pricing, resourcing, and engagement terms. Our domain expertise is in Banking and Payments, Healthcare, Manufacturing, Retail, Automotive, Travel and Transportation, and Pharma.
  • Promoting citizen data scientist – “According to Gartner, citizen data scientists can bridge the gap between mainstream self-service analytics by business users and the advanced analytics techniques of data scientists.” Any solution that we build is envisioned and executed with a focus to drive self-service analytics by business users, and gradually growing them as citizen data scientists.
  • Ever growing experience – As data sciences evolve around various aspects of advance analytics, we keep demonstrating our solutions around AI Digital assistant, HR Analytics, Telematics, Risk and Fraud Analytics across multiple segments, such as autonomous vehicles (Driver Distraction Program), product recommendations, and other new features for different business services.

The Guide has been authored by Gartner’s global team of data and analytics specialists, Jorgen Heizenberg, Alexander Linden, Jim Hare, Nigel Shen and Ehtisham Zaidi. It is an excellent resource for CIOs, CTOs and IT managers planning on DS&ML programs in their business in 2017 & 2018.

Two ways to read the full report:

If you are a Gartner member, go here: https://www.gartner.com/document/3822963?ref=solrResearch&refval=193628552&qid=

Would like us to send you a copy? Write to us here: mcommunicationin@www.altimetrik.com
Rangarajan Seetharaman

Rangarajan Seetharaman

Latest Reads

Subscribe

Suggested Reading

Ready to Unlock Yours Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes